Cannabis Industry Predictions for 2020: Will Pot Stocks Bounce Back?

cannabis industry

The cannabis industry is coming out of a turbulent year in the markets, with a few scrapes and bruises, several notable wins, and a handful of losses among market participants.

After a monumental 2018, which included Canada and several US states legalizing recreational cannabis, the FDA approving the first cannabis-based treatment, and sky-high company valuations, 2019 was filled with uncertainty and, in some cases, major losses.

Weak sales performances and regulatory issues sent pot stocks to record lows last year, with the top six publicly-traded cannabis companies losing a combined $25 billion in market value since last spring.

In fact, the state of the cannabis market became so dire that Acreage Holdings (OTCQX:ACRGF) CEO Kevin Murphy referred to last year as the "2008 for the cannabis industry."

Despite the laundry list of setbacks, many industry experts are confident that the cannabis industry will make a much-needed comeback in 2020.

Let's take a look at cannabis industry predictions for 2020 and which companies are expected to do well in the next 12 months.

Legalization is Going Global

In 2013, Uruguay became the first country to fully legalize recreational marijuana. Then, in 2018, Canada followed suit. Moving into 2020, the cannabis industry is expected to spread its roots globally.

Both Luxembourg and Switzerland are on the verge of legalization, which would make the European cannabis market an attractive investment opportunity. Meanwhile, New Zealand will hold an adult-use cannabis referendum in September to vote on the proposed Cannabis Legalization and Control Bill.

And then there is Mexico, which was poised to become the third country to legalize recreational marijuana until the country missed its deadline on November 1, 2019. The Supreme Court of Mexico granted lawmakers a six-month extension, meaning a decision is expected by the end of April.

If and when the legalization bill passes in Mexico, Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) will be ready to capitalize on the new market. In fact, the company has been awaiting this moment since it acquired Farmacias Magistrales S.A. in December 2018.

Another company with a stake in the Mexico market is CannaOne Technologies Inc. (CSE:CNNA) (OTCPK:CNONF), which signed a contract with Manna Health Services SA de CV last March to launch an online CBD product purchase and delivery marketplace in Mexico.

>> TGOD Stock Continues to Be Affected by Financing Uncertainty

The CBD Market Will Continue to Grow

Speaking of CBD, many experts see this market maturing greatly in 2020 and rivaling the cannabis industry in size. Since the passing of the updated US Farm Bill in December 2018, the CBD market has been gaining steam and popping up in virtually every industry.

Now, CBD-infused offerings can be found in everything from skincare and makeup to food and beverages; even CBD pet products are becoming commonplace. Big box retailers like CVS (NYSE:CVS) and Walmart (NYSE:WMT) have already lined their shelves with CBD products, and others are expected to follow suit as consumers become more educated on the benefits on the non-psychoactive compound.

The CBD market is expected to grow rapidly in the next few years to reach $22 billion by 2022.

More and more countries around the world are legalizing CBD products for either medical or recreational use, with Australia being the most recent to consider over-the-counter cannabidiol product sales.

One of the biggest barriers for the CBD industry is ensuring that the products on the market meet high-quality standards and guidelines. At present, CBD products remain unregulated, meaning there is little legal oversight in regards to the level of CBD in them.

Investors who are interested in the CBD market may want to stick to companies that conduct clinical trials and can back up their products with scientific evidence.

Companies that come to mind are Charlotte's Web Holdings (TSX:CWEB) (OTCQX:CWBHF), CV Sciences Inc. (OTCQB:CVSI), and Australia's Elixinol Global (OTCQX:ELLXF).

Company Outcomes Will Become the Focus

After lackluster revenue from the cannabis industry's major players, the focus in 2020 will likely be on cannabis companies that are turning a profit or, at the very least, displaying solid profit-centric growth.

In the third quarter of 2019, the cannabis industry's "Big Four"—Aurora Cannabis Inc., Canopy Growth (TSX:WEED) (NYSE:CGC), Cronos Group (NASDAQ:CRON), and Tilray (NASDAQ:TLRY)—all posted less-than-stellar financial results.

When these industry leaders missed the mark, it sent their stocks on a downward spiral and shone a spotlight on the fact that these companies received sky-high valuations without having the sales numbers to back them up.

Moving into 2020, investors will likely tread lightly to prevent being burned by empty promises from cannabis companies.

Canadian Cannabis 2.0

Although Cannabis 2.0 technically began in October 2019, the Health Canada 60-day notice period that pushed back cannabis derivative products launches this year.

The beginning of 2020 saw several cannabis companies roll out cannabis edibles and beverages to the awaiting Cannabis 2.0 market, which is expected to bring in C$2.7 billion annually, and many more are expected to follow suit in the coming months.

It is still too early to tell which Canadian cannabis stocks will lead the edibles market, but some believe cannabis extraction companies will be the biggest winners.

One company of particular interest is Valens GroWorks (TSXV:VLNS) (OTCQX:VLNCF), an extraction company with several high-profile clients including Canopy Growth, HEXO (TSX:HEXO) (NYSE:HEXO), Organigram  Holdings (TSX:OGI) (NASDAQ:OGI), and Tilray. Valens also has white-label deals with BRNT and Shopper's Drug Mart.

MediPharm Labs (TSX:LABS) (OTCQX:MEDIF) is another extraction company that is expected to profit from the Cannabis 2.0 market. The company takes the cake as the largest extraction provider based on sales and has an extraction capacity of 300,000 kilograms per year. Like Valens, MediPharm has acquired a decent roster of clients, including the Supreme Cannabis Company (TSX:FIRE) (OTCQX:SPRWF) and Cronos Group.

Are there any cannabis industry trends you are excited about in 2020? Let us know in the comments!

>> Read More Investing & Finance News

Featured Image: DepositPhotos © olanstock

Please See Disclaimer

If You Liked This Article Click To Share


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on their research and understanding of the sector.

2) The Article was issued on behalf of a third party, CannaOne Technologies Inc. Market Jar Media Inc. has or expects to receive 125,000 options of CannaOne Technologies Inc. from 3/18/2019 to 3/18/2020.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.